KIDS vs. EYE, ENOV, CNMD, NVCR, SSII, CDRE, BLFS, ESTA, PLSE, and MDXG
Should you be buying OrthoPediatrics stock or one of its competitors? The main competitors of OrthoPediatrics include National Vision (EYE), Enovis (ENOV), CONMED (CNMD), NovoCure (NVCR), SS Innovations International (SSII), Cadre (CDRE), BioLife Solutions (BLFS), Establishment Labs (ESTA), Pulse Biosciences (PLSE), and MiMedx Group (MDXG). These companies are all part of the "medical equipment" industry.
OrthoPediatrics vs. Its Competitors
National Vision (NASDAQ:EYE) and OrthoPediatrics (NASDAQ:KIDS) are both small-cap medical equipment companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, institutional ownership, earnings, media sentiment and analyst recommendations.
National Vision has higher revenue and earnings than OrthoPediatrics. National Vision is trading at a lower price-to-earnings ratio than OrthoPediatrics, indicating that it is currently the more affordable of the two stocks.
In the previous week, National Vision had 1 more articles in the media than OrthoPediatrics. MarketBeat recorded 8 mentions for National Vision and 7 mentions for OrthoPediatrics. OrthoPediatrics' average media sentiment score of 1.61 beat National Vision's score of 1.43 indicating that OrthoPediatrics is being referred to more favorably in the news media.
69.1% of OrthoPediatrics shares are owned by institutional investors. 2.7% of National Vision shares are owned by company insiders. Comparatively, 32.7% of OrthoPediatrics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
National Vision has a net margin of -0.75% compared to OrthoPediatrics' net margin of -18.92%. National Vision's return on equity of 3.56% beat OrthoPediatrics' return on equity.
National Vision currently has a consensus price target of $24.73, suggesting a potential upside of 5.67%. OrthoPediatrics has a consensus price target of $34.14, suggesting a potential upside of 59.25%. Given OrthoPediatrics' stronger consensus rating and higher probable upside, analysts clearly believe OrthoPediatrics is more favorable than National Vision.
National Vision has a beta of 1.27, indicating that its stock price is 27% more volatile than the S&P 500. Comparatively, OrthoPediatrics has a beta of 1.12, indicating that its stock price is 12% more volatile than the S&P 500.
Summary
National Vision and OrthoPediatrics tied by winning 8 of the 16 factors compared between the two stocks.
Get OrthoPediatrics News Delivered to You Automatically
Sign up to receive the latest news and ratings for KIDS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding KIDS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
OrthoPediatrics Competitors List
Related Companies and Tools
This page (NASDAQ:KIDS) was last updated on 8/28/2025 by MarketBeat.com Staff